- Home
- KNOP vs IPHA Comparison
KNOP vs IPHA Comparison
Compare KNOP & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KNOP
- IPHA
- Stock Information
- Founded
- KNOP 2013
- IPHA 1999
- Country
- KNOP United Kingdom
- IPHA France
- Employees
- KNOP N/A
- IPHA N/A
- Industry
- KNOP Marine Transportation
- IPHA Biotechnology: Pharmaceutical Preparations
- Sector
- KNOP Consumer Discretionary
- IPHA Health Care
- Exchange
- KNOP Nasdaq
- IPHA Nasdaq
- Market Cap
- KNOP 187.6M
- IPHA 148.3M
- IPO Year
- KNOP 2013
- IPHA 2019
- Fundamental
- Price
- KNOP $5.91
- IPHA $1.69
- Analyst Decision
- KNOP
- IPHA Strong Buy
- Analyst Count
- KNOP 0
- IPHA 1
- Target Price
- KNOP N/A
- IPHA $11.50
- AVG Volume (30 Days)
- KNOP 104.2K
- IPHA 49.9K
- Earning Date
- KNOP 02-24-2025
- IPHA 09-12-2024
- Dividend Yield
- KNOP 1.76%
- IPHA N/A
- EPS Growth
- KNOP N/A
- IPHA N/A
- EPS
- KNOP N/A
- IPHA N/A
- Revenue
- KNOP $299,790,000.00
- IPHA $36,202,722.00
- Revenue This Year
- KNOP $7.66
- IPHA N/A
- Revenue Next Year
- KNOP $1.75
- IPHA $101.65
- P/E Ratio
- KNOP N/A
- IPHA N/A
- Revenue Growth
- KNOP 4.75
- IPHA N/A
- 52 Week Low
- KNOP $4.94
- IPHA $1.29
- 52 Week High
- KNOP $9.11
- IPHA $3.51
- Technical
- Relative Strength Index (RSI)
- KNOP 51.68
- IPHA 42.95
- Support Level
- KNOP $5.87
- IPHA $1.60
- Resistance Level
- KNOP $6.13
- IPHA $1.87
- Average True Range (ATR)
- KNOP 0.23
- IPHA 0.13
- MACD
- KNOP 0.02
- IPHA -0.04
- Stochastic Oscillator
- KNOP 56.25
- IPHA 16.67
About KNOP KNOT Offshore Partners LP Common Units representing Limited Partner Interests
KNOT Offshore Partners LP owns, operates, and shuttles tankers under long-term charters in the North Sea and Brazil. The company provides crude oil loading, transportation, and storage services under time charters and bareboat charters. The Partnership is formed for acquiring ownership interests in over four shuttle tankers owned by Knutsen NYK Offshore Tankers AS (KNOT). It operates through the shuttle tanker market segment.
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.